Hypercatecholaminemia in Reye's syndrome.
To evaluate the role of catecholamines in Reye's syndrome, a specific and sensitive radioenzymatic assay was used to study plasma and CSF concentration of dopamine, norepinephrine, and epinephrine in 14 patients with liver-biopsy-proven Reye's syndrome. The results (median and range) revealed significant (P less than .04, P less than .0024, and P less than .030, respectively) elevation in plasma dopamine (131, 0 to 1,193 pg/mL), norepinephrine (1,455, 20 to 5,271 pg/mL), and epinephrine (345, 7.6 to 2,504 pg/mL) at the onset of the disease when compared with the level of these neurotransmitters in a group of hospitalized patients without hepatic disorders. There was a positive correlation between plasma catecholamines and stage of coma on admission (r = .54 to .86; P less than .001 to .024). Furthermore, the concentration of dopamine, norepinephrine, and epinephrine in the CSF increased significantly during the development of cerebral edema in all patients with Reye's syndrome as compared with concentrations in a control population. Hypercatecholaminemia may contribute to the encephalopathy of Reye's syndrome.
D000293:Adolescent; D001929:Brain Edema / Q000209:etiology; D002395:Catecholamines / Q000097:blood* / Q000134:cerebrospinal fluid; D002648:Child; D002675:Child, Preschool; D003128:Coma / Q000209:etiology; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D012202:Reye Syndrome / Q000097:blood* / Q000628:therapy; D014439:Tyramine / Q000097:blood / Q000652:urine
D002395:Catecholamines; D014439:Tyramine